3Zhao-You Tang Liver Cancer Institute & Zhongshan Hospital of Fudan University Professor of Surgery Chairman.Liver Cancer Institute of Fudan University(previous Liver Cancer Institute of Shanghai Medical University)136 Yixueyuan Road,Zhongshan Hospital,Shanghai 200032,China..Hepatocellular Carcinoma-Cause,Treatment and Metastasis[J].World Journal of Gastroenterology,2001,7(4):445-454. 被引量：214
4Zhao-You Tang Fan-Xian Sun Jian Tian Sheng-Long Ye Yin-Kun Liu Kang-Da Liu Qiong Xue Jie Chen Jing-Lin Xia Lun-Xiu Qin Hui-Chuan Sun Lu Wang Jian Zhou Yan Li Zeng-Chen Ma Xin-Da Zhou Zhi-Quan Wu Zhi-Ying Lin Bing-Hui Yang Liver Cancer Institute of Fudan University and Zhongshan Hospital,Shanghai 200032,China.Metastatic human hepatocellular carcinoma models in nude mice and cell line with metastatic potential[J].World Journal of Gastroenterology,2001,7(5):597-601. 被引量：34
1Humlg WL,Zhu XE. Signal transduction[M]. Beijing: People's Medical Publishing House ,2005 : 151-99.
2Cheng GZ,Park S,Shu S,et al. Adances of Akt pathway in human onco- gensis and as a target for anti-cancer drug discovery. [J] Curr Cancer Drug Targets,2008 ;8( 1 ) :2-6.
3Vlahos CJ, Matter WF, Hui KY, et al. A specific inhihitor of phosphati- dylinositol-3-kinase, 2-( 4-mor-pholinyl )-$-phenyl4H-l-benzopyran-4- One ( LY294002 ) [J]. Biol Chem, 1994 ;269 ( 7 ) :5241-8.
4Barancik M, Bohacova V, Sedlak J,et al. LY294002, a specific inhibitor of PI3K/Aktkinase pathway, antagonizes P-glycoprotein-mediated muhidrug resistance [ J ]. Eur J Pharm Sci,2006 ;29 ( 5 ) :426.
5Ma J. PTEN regulate angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells[J] Mole Cell Biochem ,2009; 11 (351) :161-71.
6Chao X,Zao J, Gu XY,et aL Blocking of PI3K/Akt imtuces apoptosis by its effect on NF-KB activity in gastriccarcinoma cell line SGC7901[J]. Biomed Pharmacother,2010; I 1 (64) :6004.
7Wong KK,Engelman JA, Cantley LC. Targeting the PI3K signaling path- way in cancer[J]. Curr Opin,2010;2(20) :87-90.
8Martelli AM,Evangelisti C, Chiarini F,et al. The phosphatidylinosi-tol 3- kinase/Akt/mTOR signaling network as a therapeutic target in acute my- elogenous leukemia patients[J]. Oncotarget,2010;6( I ) :89-103.
